Business
ARIUS is one of Canada's Top 10
ARIUS is one of Canada's Top 10.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\n\nTORONTO, Nov. 20 /CNW/ - ARIUS Research Inc. (\"ARIUS\") (TSX: ARI), has\nbeen named one of Canada's Top 10 Life Sciences Companies. Arius is dedicated\nto the discovery of breakthrough cancer treatments through a unique approach\nto screening for antibody drug candidates. ARIUS has attracted the attention\nof large pharmaceutical companies and investors because of its focus on\nantibodies with the potential to kill cancer cells while leaving normal cells\nalone.\n\"ARIUS has gone through a transformation this year, with the completion\nof a large financing, a licensing deal, a research collaboration deal, and\ngraduation to the Toronto Stock Exchange\", said Dr. David S. Young, President\nand CEO of ARIUS, \"It is particularly gratifying to have our efforts\nrecognized by the Canadian Lifesciences Community and to be among the best\ncompanies out there.\"\nAs one of Canada's Top 10, ARIUS will present to an audience of venture\ncapitalists, potential strategic alliance partners and conference delegates at\nBioNorth 2006 - one of North America's premier life science conferences. ARIUS\nwill also participate in exclusive investment forums in New York and Boston in\nJanuary 2007 and will have the opportunity to exhibit at BIO2007.\nWinning companies in Canada's Top 10 Life Sciences Competition, are\nselected from a pool of entrants by an independent international jury of life\nscience venture capitalists. Based on their expert knowledge of investment in\nthe life sciences sector, the jury selects the companies that offer the best\ninvestment and partnership prospects.\n\nAbout ARIUS\nARIUS Research Inc. is a biotechnology company dedicated to personalizing\ncancer therapy through the discovery and development of novel anticancer\nmonoclonal antibodies (MAbs). Established in 1999, ARIUS has built a\nproprietary technology platform, FunctionFIRST(TM), that rapidly identifies\npowerful MAbs targeting a variety of cancer indications. This antibody\ngeneration engine has enabled ARIUS to assemble a growing pipeline, which is\nused for commercial collaborations and in-house development. ARIUS has ongoing\npartnerships with key biotechnology and drug development companies. The\ncompany is listed on the TSX under the symbol \"ARI\".\n\nForward-Looking Statement\nCertain statements in this news release constitute \"forward-lookin...